Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.

@article{Emslie2007VenlafaxineEF,
  title={Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.},
  author={Graham J. Emslie and Robert L. Findling and Paul P. Yeung and Nadia R. Kunz and Yunfeng Li},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2007},
  volume={46 4},
  pages={
          479-88
        }
}
  • G. Emslie, R. Findling, Yunfeng Li
  • Published 1 April 2007
  • Medicine, Psychology
  • Journal of the American Academy of Child and Adolescent Psychiatry
OBJECTIVE The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001. METHOD Participants received venlafaxine ER (flexible dose, based on body weight; intent to treat, n = 169) or placebo (intent to treat, n = 165) for up to 8 weeks. The primary efficacy variable was the change from… 
View on PubMed
doi.org
109 Citations
Highly Influential Citations
3
Background Citations
20
Methods Citations
5
Results Citations
6

109 Citations

Citation Type

Citation Type

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
TLDR
Low and high exposure desvenlafaxine groups did not demonstrate efficacy for the treatment of MDD in children and adolescents in this double-blind, placebo-controlled trial.
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
TLDR
Neither desvenlafaxine nor the reference medication, fluoxetine, demonstrated a statistically significant difference from placebo on the primary endpoint, and this was considered a failed trial and no efficacy conclusions can be drawn.
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
TLDR
Vilazodone was generally safe and well tolerated, with treatment-emergent AEs similar to those in adult patients, and suicidal behavior in adolescent patients could not be confirmed in this study.
Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents with Major Depressive Disorder
TLDR
Most improvement with venlafaxine ER occurs during the first 6 weeks of treatment, and cribers should be alert to signs of suicidal ideation and hostility in pediatric patients.
Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis.
Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.
OBJECTIVE The authors examined characteristics and predictors of response to placebo in all available reports of short-term randomized controlled trials of antidepressants for pediatric major…
Venlafaxine extended release in pediatric anxiety and depression
TLDR
Results from completed studies show improvement in generalized and social anxiety symptoms in children and adolescents, but only minimal improvement in depressive symptoms in adolescents, with no improvement in children.
Efficacy of antidepressants in juvenile depression: meta-analysis
TLDR
Antidepressants of all types showed limited efficacy in juvenile depression, but fluoxetine might be more effective, especially in adolescents.
Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.
TLDR
Desvenlafaxine was generally safe and well tolerated in children and adolescents for treatment up to 8 weeks and AUC values increased linearly with dose; body weight alone provided an adequate prediction for dose-normalized AUC.
Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.
TLDR
Treatment with citalopram reduced depressive symptoms to a significantly greater extent than placebo treatment and was well tolerated in this population of children and adolescents.
Venlafaxine in the treatment of children and adolescents with major depression.
TLDR
The statistical analysis indicated a significant improvement over time, but it could not be attributed to venlafaxine drug therapy, and the findings did, however, suggest a low side-effect profile.
Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
TLDR
Paroxetine and clomipramine exhibit similar efficacy in adolescent depression, and these data support the serotonin hypothesis but do not confirm it in the absence of a placebo arm.
Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
TLDR
The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.
A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
TLDR
Fluoxetine was superior to placebo in the acute phase treatment of major depressive disorder in child and adolescent outpatients with severe, persistent depression, and complete remission of symptoms was rare.
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
TLDR
Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients.
Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression.
TLDR
Although both treatment groups showed substantial response, at the end of treatment a substantial proportion of patients still had MDD of subsyndromal symptoms of depression, and this and other studies of tricyclic antidepressants question the use of this medication as first-line treatment for youths with MDD.
Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.
TLDR
Paroxetine demonstrated significantly greater improvement compared with placebo in Hamilton Rating Scale for Depression total score < or = 8, HAM-D depressed mood item, K-SADS-L depressed Mood item, and CGI score of 1 or 2.
Suicidality in pediatric patients treated with antidepressant drugs.
TLDR
Use of antidepressant drugs in pediatric patients is associated with a modestly increased risk of suicidality, and a meta-analysis was conducted to obtain overall suicidity risk estimates.
Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis.
TLDR
In short-term, placebo-controlled, pediatric studies of antidepressants, active drug treatment was associated with a rate of serious suicidal events almost twice that of placebo.
...
1
2
3
...